(877) 320-5131 Menu
(877) 320-5131
Contact
Patient Portal

Recruiting

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer


Jounce : Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb)JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor ExperiencedAdult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer


"LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure"


Mirati: 516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy


Novartis Canopy A: A phase III, multicenter, randomized, double blind, placebocontrolledstudy evaluating the efficacy and safety ofcanakinumab versus placebo as adjuvant therapy in adultsubjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cmN2) completely resected (R0) non-small cell lung cancer(NSCLC)

Upcoming

A PHASE 2 OPEN LABEL STUDY OF SACITUZUMABGOVITECAN (IMMU-132) IN SUBJECTS WITHMETASTATIC SOLID TUMORS:


Amgen: AMG 510: 20190009: A Phase 3 Multicenter, Randomized, OpenLabel, Active-controlled, Study of AMG 510Versus Docetaxel for the Treatment of previouslytreated Locally Advanced and unresectable orMetastatic NSCLC Subjects with Mutated KRASp.G12C:


Astellas: An Open-Label, Multicenter, Multi-Cohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202):


Boehringer Ingelheim - 1336-0011 - 6 cohorts Basket: An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors:


Boehringer Ingelheim - 1336-0011 - 6 cohorts Basket: An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors:


Pfizer C3651009: A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF 06946860 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND CACHEXIA:


Pfizer: (EZH2): 235999: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITHRELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULARLYMPHOMA (FL):

Not Recruiting

"A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent "


"A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1"


"A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression"


"GEODE: Registry of Guardant360® Use and Outcomes In People With Advanced Cancer Including:

  • Module 1: Non-Small Cell Lung Cancer (NSCLC)
  • Protocol Number: 01-MX-003"

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer


"Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung CancerPhase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)"

Schedule a Consultation

Your health is important, and we welcome the opportunity to help you heal.


To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or Click the link below to access our Online Appointment Request

Book An Appointment

© Beverly Hills Cancer Center. All Rights Reserved. Web Design & Internet Marketing by Studio III

Privacy Policy

Rate Us
Rate us on Google Rate us on Yelp Rate us on HealthGrades Rate us on Facebook Rate us on Yahoo! Rate us on WebMD
Contact Us